Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

Nextgen Platform Combines VectorBuilder and Maxcyte Technologies to Boost Clinical-Grade Cell Engineering

Nextgen Platform Combines VectorBuilder and Maxcyte Technologies to Boost Clinical-Grade Cell Engineering

Published

on

VectorBuilder and MaxCyte formed a strategic partnership focused on co-developing a new gene delivery solution using VectorBuilder’s MiniVec™ plasmid system and MaxCyte’s clinical electroporation platform for ex vivo cell engineering.

Officials at both companies say that ex vivo cell therapies such as CAR-T, CAR-NK, and iPSC-based treatments have gained significant traction, but critical challenges in safety and manufacturability continue to limit their broader application. They explain that existing gene delivery methods present significant trade-offs: traditional electroporation of conventional DNA or RNA often results in poor target cell viability or limited therapeutic durability, while lentiviral vectors, though widely used, carry high production costs and potential safety risks such as malignancy arising from vector integration into the host genome.

What is collectively needed, both companies maintain, are more efficient, safer, and scalable approaches to cell engineering.

The partnership between VectorBuilder and MaxCyte has been designed to address these challenges by developing the next-generation electroporation-based ex vivo gene delivery solution through the integration of VectorBuilder’s MiniVec backbone with MaxCyte’s Flow Electroporation® technology.

MiniVec is described as a miniaturized plasmid backbone that eliminates the need for antibiotic- or additive-based selection during fermentation to simplify translation to GMP-grade production. Its reduced prokaryotic sequences have been shown to improve yield and performance across a broad range of applications, according to VectorBuilder.

Flow Electroporation relies on a continuous-flow process that reduces cellular stress, preserving cell viability and functionality while enabling scalable, highly efficient gene delivery. This two-pronged approach is designed to deliver significantly improved cell viability and higher transfection efficiency compared to conventional models, pointed out Maher Masoud, president and CEO of MaxCyte.

“Cell therapy development requires delivering therapies that are manufacturable, scalable, and commercially viable,” he said. “We believe we can enable a new standard for nonviral gene delivery—one that enhances cell quality, improves manufacturing efficiency, and provides developers with a more streamlined path from research through commercialization.”

“This partnership combines our complementary strengths to establish a next-generation platform for efficient, safe, and scalable electroporation-based cell engineering for therapies such as CAR-T.

“As both companies have extensive expertise in GMP-compliant clinical development solutions, the combined platform is well aligned to enable a seamless development pipeline from clinical trials through to commercialization,” noted Bruce Lahn, PhD, founder and chief scientist of VectorBuilder. “Our aim is to provide a platform delivering high-end performance with an optimal cost-of-goods and price-per-dose model to ease scale-up, commercial strategy, and fundraising efforts for drug developers.”

The post Nextgen Platform Combines VectorBuilder and Maxcyte Technologies to Boost Clinical-Grade Cell Engineering appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

New webinar: Tackling drug discovery challenges in cancer research

Published

on

Cancer cells

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.

You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.

Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.

Q&A with the speakers follows the presentations.

Register for free now.

The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).

Continue Reading

Uncategorized

Psilocybin proves promising in neuropathic pain mouse study

Published

on

Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.

Continue Reading

Uncategorized

New Spectrometry Technique Could Aid Formulation Development

New Spectrometry Technique Could Aid Formulation Development

Published

on

A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.

According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.

“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”

Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.

The challenge is understanding the link between these things within a heterogeneous sample, he says.

To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.

He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.

Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.

Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.

The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Trending

Helixgate Biotech Review July Issue QR CodeScan to Read